Illustration depicts T lymphocytes attacking a migrating cancer cell. Novel ways to improve the ability of T lymphocytes to enhance immune response are under study.
Mary L. (Nora) Disis, MD
Professor, Medicine and Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA
|Newly diagnosed, metastatic renal cell carcinoma||Autologous dendritic cells loaded with patient's messenger RNA||Argos Therapeutics||Phase III ADAPT trial to start mid-2012; FDA Fast Track designation|
|Stage I/II pancreatic adenocarcinoma after surgical resection||2 separate allogenic pancreatic cancer cell lines engineered to express a-Ga||NewLink Genetics Corporation||Phase III under way; FDA Fast Track designation|
|Allovectin-7||First-line treatment for stage III/IV melanoma||Plasmid/lipid-based, encoding DNA sequences for HLA-B7 and β2 microglobulin to form an MHC class I complex||Vical/AnGes MC||Phase III trial in final stages of patient follow-up; FDA Fast Track designation|
|BiovaxID||Indolent follicular non-Hodgkin lymphoma||Hybridoma-derived idiotype vaccine made from patient's tumor cells||Biovest International/ National Cancer Institute||Phase III trial completed; FDA filing planned|
|IMA901||Advanced/metastatic renal cell carcinoma||Combination of multiple tumor-associated peptides||immatics biotechnologies GmbH||Phase III trial under way|
|Lucanix||Stage IIIB/IV NSCLC after 0-5 prior chemotherapy treatments||Four NSCLC cell lines gene-modified to block the secretion of TGF-β||NovaRx Corporation||Phase III trial under way; FDA Fast Track designation|
|MAGE-A3||Melanoma, NSCLC||Recombinant antigen-specific cancer immunotherapeutic||GlaxoSmithKline||Phase III trials under way|
|Multikine||Advanced primary squamous cell carcinoma of the oral cavity/soft palate||Mixture of cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors||CEL-SCI Corporation/Teva Pharmaceuticals Industries/ Orient Europharma||Phase III trial under way|
|NeuVax||Early-stage, node-positive breast cancer with low-to-intermediate HER2 expression||Peptide derived from HER2 combined with GM-CSF||Galena Biopharma||Phase III PRESENT trial under way|
|PROSTVAC||Asymptomatic or minimally symptomatic castration-resistant prostate cancer||Sequentially dosed combination of Vaccinia and Fowlpox poxviruses that encode prostate-specific antigen plus three immune-enhancing costimulatory molecules||Bavarian Nordic A/S||Phase III PROSPECT trial under way|
|Surgically resected, EGFRvIII-positive glioblastoma||Consists of EGFRvIII antigen chemically conjugated to the protein keyhole limpet hemocyanin||Celldex Therapeutics||Phase III ACT IV Study under way|
|Stimuvax||Unresectable stage III NSCLC in patients with response or stable disease after ≥2 cycles of chemo-radiotherapy||25-amino acid sequence of the cancer-associated marker MUC-1 in a liposomal formulation||Oncothyreon/Merck KGaA||Phase III START trial under way|
|Unresectable stage IIIB/IIIC/IV melanoma||Herpes simplex virus type 1 engineered to express GM-CSF||Amgen||Phase III study under way|
|Stage IV NSCLC||Modified Vaccinia virus vector expressing the MUC1 antigen and interleukin-2||Transgene/Novartis||Phase IIB/III trial under way|
EGFRvIII indicates epidermal growth factor receptor variant III; GM-CSF, granulocyte macrophage colony-stimulating factor; NSCLC, non-small cell lung cancer.
Cancer Research Institute and MD Becker Partners. Cancer immunotherapy: a roundtable discussion. MD Becker website. http://mdbpartners.com/?s=roundtable. Published June 30, 2011. Accessed June 6, 2012. Securities and Exchange Commission filings, annual reports, press releases for individual companies.
|Title||Expiration Date||CME Credits|
|Online Medical Crossfire®: 5th Annual Miami Lung Cancer Conference||May 30, 2019||6.5|
|Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?||May 31, 2019||1.5|